{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:12:21Z","timestamp":1760148741463,"version":"build-2065373602"},"reference-count":15,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Vulvovaginal atrophy (VVA) is a condition that affects a large number of women and can significantly impact their quality of life. While several treatments are currently available for VVA, there are potential risks associated with their use. Non-hormonal medical devices have been developed to treat VVA, offering a potential alternative to traditional hormone-based therapies. This study aimed to evaluate the safety and efficacy of the combined treatment with two medical devices, Plurigin Ovules and Plurigin Solution, used as an adjuvant in the treatment of VVA. Materials and Methods: This is a retrospective, observational study. Data were collected from medical records of all patients who received the combination treatment of both medical devices as part of normal clinical practice for the treatment of VVA. The performance of the medical devices was analyzed using the THIN Prep. A comprehensive physical examination and gynecological evaluation were conducted before the initiation of treatment (day 0), as well as at follow-up 1 (day 90), follow-up 2 (day 180), and follow-up 3 (day 270). Data analysis included descriptive analysis and statistical tests. Results: The study included 76 women (mean age: 59 years). At follow-up 3, 61% of the respondents demonstrated improved THIN Prep results and symptom resolution (p &lt; 0.001; CI [0.5003, 0.7197]). Moreover, the percentage of patients reporting dyspareunia, burning, and irritation decreased over the course of the study, with the majority of patients reporting no symptoms at follow-up 3. Conclusions: The use of Plurigin Ovules plus Plurigin Solution may be an effective treatment option for VVA, improving vaginal health, alleviating symptoms, and improving sexual function, leading to improved quality of life for women suffering from this condition. However, the study has limitations, such as its retrospective nature, and further studies are needed to confirm the efficacy and safety of these devices.<\/jats:p>","DOI":"10.3390\/medicina59061108","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T01:34:32Z","timestamp":1686188072000},"page":"1108","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plurigin Ovules and Plurigin Solution in the Treatment of Vulvovaginal Atrophy in Menopausal Women: A Retrospective Monocentric Observational Study"],"prefix":"10.3390","volume":"59","author":[{"given":"Daniele","family":"Langella","sequence":"first","affiliation":[{"name":"Unit\u00e0 Operativa Materno Infantile, Distretto 57 ASL Napoli 3 Sud, 80059 Torre del Greco, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1210\/jc.2009-2509","article-title":"Postmenopausal hormone therapy: An endocrine society scientific statement","volume":"95","author":"Santen","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal Atrophy","volume":"85","author":"Rhodes","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/13697137.2010.522875","article-title":"Recommendations for the management of postmenopausal vaginal atrophy","volume":"13","author":"Sturdee","year":"2010","journal-title":"Climacteric"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41591-019-0600-6","article-title":"Vaginal microbiome transplantation in women with intractable bacterial vaginosis","volume":"25","author":"Cohen","year":"2019","journal-title":"Nat. Med."},{"key":"ref_5","first-page":"481","article-title":"Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"key":"ref_6","first-page":"111","article-title":"Genitourinary Syndrome of Menopause","volume":"10","author":"Patni","year":"2019","journal-title":"J. Midlife Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.maturitas.2016.09.013","article-title":"Female sexual dysfunction (FSD): Prevalence and impact on quality of life (QoL)","volume":"94","author":"Nappi","year":"2016","journal-title":"Maturitas"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"46.e1","DOI":"10.1016\/j.ajog.2011.07.024","article-title":"The ATHENA human papillomavirus study: Design, methods, and baseline results","volume":"206","author":"Wright","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fendo.2019.00561","article-title":"Addresing Vulvovaginal Atrophy (VVA)\/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women","volume":"10","author":"Nappi","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1743-6109.2004.10105.x","article-title":"Summary of the recommendations on sexual dysfunctions in women","volume":"1","author":"Basson","year":"2004","journal-title":"J. Sex. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jsxm.2016.09.020","article-title":"Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions\u2014Part II","volume":"13","author":"Parish","year":"2016","journal-title":"J. Sex. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jsm.12190","article-title":"Vulvar and vaginal atrophy in postmenopausal women: Findings from the REVIVE (REal Women\u2019s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey","volume":"10","author":"Kingsberg","year":"2013","journal-title":"J. Sex. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/GME.0000000000000571","article-title":"Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause","volume":"23","author":"Labrie","year":"2016","journal-title":"Menopause"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1743-6109.2007.00409.x","article-title":"Sexual dysfunctions: Classifications and definitions","volume":"4","author":"Hatzimouratidis","year":"2007","journal-title":"J. Sex. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1108\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:50:19Z","timestamp":1760125819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["medicina59061108"],"URL":"https:\/\/doi.org\/10.3390\/medicina59061108","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,6,7]]}}}